Cargando…

Robust Guidelines for the Management of HR+ Her2− EBC: Crucial Value of CanAssist Breast

Detalles Bibliográficos
Autores principales:	Vaid, Ashok, T., Raja, Batra, Ullas, Krishna, Vamshi Muddu, Rangrajan, Bharath, Narayanan, Prasad, Vora, Amish, Advani, Suresh H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Thieme Medical and Scientific Publishers Pvt. Ltd. 2022
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9718594/ https://www.ncbi.nlm.nih.gov/pubmed/36466976 http://dx.doi.org/10.1055/s-0042-1756179

Ejemplares similares

CanAssist Breast Impacting Clinical Treatment Decisions in Early-Stage HR+ Breast Cancer Patients: Indian Scenario
por: Sankaran, Satish, et al.
Publicado: (2019)

EBC Pre-Assembly Last Module
Publicado: (2003)

EBC Cradle + 18 modules Displacement
Publicado: (2003)

Comparison of breast cancer prognostic tests CanAssist Breast and Oncotype DX
por: Sengupta, Aditya K., et al.
Publicado: (2020)

EBC Pre-Assembly / Top part Assembly
Publicado: (2003)

The usefulness of CanAssist breast in the assessment of recurrence risk in patients of ethnic Indian origin
por: Chandra Doval, Dinesh, et al.
Publicado: (2021)

To Give or Not to Give Adjuvant Chemotherapy in Breast Cancer? Can CanAssist Breast Assist?
por: Akhade, Amol, et al.
Publicado: (2022)

New panel of microsatellite alterations detectable in the EBC for lung cancer prognosis
por: Carpagnano, Giovanna E, et al.
Publicado: (2016)

23255 Devices Engineered to Collect Exhaled Breath Condensate (EBC) and their Applications
por: Schmidt, Alexander J., et al.
Publicado: (2021)

The usefulness of CanAssist Breast over Ki67 in breast cancer recurrence risk assessment
por: Eshwaraiah, Mallikarjuna Siraganahalli, et al.
Publicado: (2023)

A comparative analysis of recurrence risk predictions in ER+/HER2− early breast cancer using NHS Nottingham Prognostic Index, PREDICT, and CanAssist Breast
por: Gunda, Aparna, et al.
Publicado: (2022)

A retrospective validation of CanAssist Breast in European early-stage breast cancer patient cohort
por: Gunda, Aparna, et al.
Publicado: (2022)

Differential clinicopathological features, treatments and outcomes in patients with Exon 19 deletion and Exon 21 L858R EGFR mutation-positive adenocarcinoma non-small-cell lung cancer
por: Batra, Ullas, et al.
Publicado: (2023)

Management of isolated recurrence of extramedullary myeloid tumor at a single site
por: Krishna, Muddu Vamshi, et al.
Publicado: (2013)

The affect of goserelin on the QoL of women having chemotherapy for EBC: Results from the OPTION trial
por: R, Leonard, et al.
Publicado: (2020)

Epigenetic study of early breast cancer (EBC) based on DNA methylation and gene integration analysis
por: Zhang, Wenshan, et al.
Publicado: (2022)

Analytical validation of CanAssist-Breast: an immunohistochemistry based prognostic test for hormone receptor positive breast cancer patients
por: Attuluri, Arun Kumar, et al.
Publicado: (2019)

Consensus guidelines for the management of HR-positive HER2/neu negative early breast cancer in India, SAARC region and other LMIC by DELPHI survey method
por: Parikh, Purvish, et al.
Publicado: (2023)

Intra-Lesional Injection of the Novel PKC Activator EBC-46 Rapidly Ablates Tumors in Mouse Models
por: Boyle, Glen M., et al.
Publicado: (2014)

An EBC/Plasma miRNA Signature Discriminates Lung Adenocarcinomas From Pleural Mesothelioma and Healthy Controls
por: Faversani, Alice, et al.
Publicado: (2021)

Reference Ranges of 8-Isoprostane Concentrations in Exhaled Breath Condensate (EBC): A Systematic Review and Meta-Analysis
por: Shoman, Yara, et al.
Publicado: (2020)

Author Correction: Epigenetic study of early breast cancer (EBC) based on DNA methylation and gene integration analysis
por: Zhang, Wenshan, et al.
Publicado: (2022)

Clinical validation of an immunohistochemistry‐based CanAssist‐Breast test for distant recurrence prediction in hormone receptor‐positive breast cancer patients
por: Bakre, Manjiri M., et al.
Publicado: (2019)

Evolving perspectives on the treatment of HR+/HER2+ metastatic breast cancer
por: Pegram, Mark, et al.
Publicado: (2023)

Usefulness of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in dermatofibrosarcoma protuberans on treatment with imatinib
por: Kashyap, Raghava, et al.
Publicado: (2016)

Pathologic response at the epicenter of the treatment decision-making process in Human Epidermal Receptor–Type 2 overexpressing (Her2+) Early Breast Cancer (EBC): Challenges and opportunities for financially-constrained healthcare systems
por: Mano, Max S.
Publicado: (2020)

Dose Characterization of the Investigational Anticancer Drug Tigilanol Tiglate (EBC-46) in the Local Treatment of Canine Mast Cell Tumors
por: Miller, Jane, et al.
Publicado: (2019)

Ten-year distant-recurrence risk prediction in breast cancer by CanAssist Breast (CAB) in Dutch sub-cohort of the randomized TEAM trial
por: Zhang, Xi, et al.
Publicado: (2023)

Sacituzumab Govitecan in HR-positive HER2-negative metastatic breast cancer
por: Nardin, Simone, et al.
Publicado: (2023)

Phase I dose-escalation study to determine the safety, tolerability, preliminary efficacy and pharmacokinetics of an intratumoral injection of tigilanol tiglate (EBC-46)
por: Panizza, Benedict J., et al.
Publicado: (2019)

Randomized controlled clinical study evaluating the efficacy and safety of intratumoral treatment of canine mast cell tumors with tigilanol tiglate (EBC‐46)
por: De Ridder, Thomas R., et al.
Publicado: (2020)

Epidemiological and clinical profile of triple negative breast cancer at a cancer hospital in North India
por: Suresh, P., et al.
Publicado: (2013)

Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
por: Ditsch, Nina, et al.
Publicado: (2019)

Preferences of Canadian Patients and Physicians for Treatment of HR+/HER2− Advanced Breast Cancer
por: Stellato, Daniel, et al.
Publicado: (2021)

American Society of Clinical Oncology 2021 Podcast: HR+, HER2− Breast Cancer
por: Cheung, Kwok-Leung
Publicado: (2021)

The Synergistic Effects of SHR6390 Combined With Pyrotinib on HER2+/HR+ Breast Cancer
por: Wang, Yukun, et al.
Publicado: (2021)

Cabazitaxel for Metastatic Castration-Resistant Prostate Cancer: Retrospective Data Analysis from an Indian Centre
por: Noronha, Vanita, et al.
Publicado: (2016)

A novel treatment strategy of HER2-targeted therapy in combination with Everolimus for HR+/HER2- advanced breast cancer patients with HER2 mutations
por: Ma, Jing, et al.
Publicado: (2022)

Prognostic impact of HER2-low positivity in patients with HR-positive, HER2-negative, node-positive early breast cancer
por: Shikata, Shohei, et al.
Publicado: (2023)

Targeted Neoadjuvant Therapies in HR+/HER2−Breast Cancers: Challenges for Improving pCR
por: Dey, Nandini, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_lt83j37pi9s49r0582boa304c0